Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-80

You all miss the point

Starpharma is going to own 22.5% of a company that will develop a drug using Starpharma's DEP platform. There is no risk to us and only upside.

Starpharma will be leveraging it's technology platform multiple times to many entities. It will be rewarded in several different ways

Whether it is equity exit model as in the deal with Medicxi

Whether it is the collaborations with other big pharmas model, turning into clinical trials with licensing deals and milestones and royalties.

Whether it is in in-house development to POC model spending millions of dollars and then selling or licensing out as with DEP CDA (Cabazitaxel, Docetaxel, Irinotecan)

Our technology platform can be compared t0 changing channels with remote control on TV using free to air and streaming. Point and Play

To coin a phrase

So much optionality

I look forward to future announcement